In Good Company with Nicolai Tangen Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness
159 snips
Jun 25, 2025 
Vas Narasimhan, the CEO of Novartis and a physician-scientist, discusses groundbreaking advancements in pharmaceuticals. He explores how AI is revolutionizing drug development and forming crucial partnerships with tech giants. Vas addresses Europe’s challenges in retaining competitiveness in the global market and emphasizes the need for coordinated reforms. He shares insights on the importance of leadership that prioritizes human connections and values resilience. His holistic approach to health and performance underscores the role of mindset and well-being in achieving innovation.
AI Snips
Chapters
Books
Transcript
Episode notes
Tech Partnerships Boost Pharma Innovation
- Strategic partnerships with tech companies like Palantir and Microsoft are key to pharma's digital transformation.
- Success depends on selecting the right use cases and integrating external tech expertise effectively.
Europe Risks Losing Pharma Innovation
- Europe's pharmaceutical competitiveness suffers from commoditization and price constraints.
- Without reform, Europe risks losing innovation, market size, and manufacturing to the US and China.
Key Reforms to Preserve European Pharma
- Vas advocates a Europe-wide drug price list adjusted by GDP, no pharmaceutical growth caps, and eliminating generics price propping.
- These reforms would spur innovation investment and sector growth.
